eLife:靶向衰老细胞 阻止干细胞紊乱和糖尿病

2016-01-11 佚名 生物谷

最近,来自美国梅奥诊所的研究人员在阻止和逆转衰老相关干细胞紊乱和代谢疾病方面迈出重要一步。他们在这项研究中发现了改善正常衰老小鼠体内上述问题的新方法。相关研究结果发表在国际学术期刊eLife上。   文章作者James Kirkland表示:"我们的工作表明通过特定药物靶向老年人体内的衰老细胞,阻止衰老细胞释放毒性蛋白促进糖尿病和干细胞紊乱的发生,这是完全可能的。"  

最近,来自美国梅奥诊所的研究人员在阻止和逆转衰老相关干细胞紊乱和代谢疾病方面迈出重要一步。他们在这项研究中发现了改善正常衰老小鼠体内上述问题的新方法。相关研究结果发表在国际学术期刊eLife上。

 
文章作者James Kirkland表示:"我们的工作表明通过特定药物靶向老年人体内的衰老细胞,阻止衰老细胞释放毒性蛋白促进糖尿病和干细胞紊乱的发生,这是完全可能的。"
 
在这项研究中,研究人员发现人类衰老的脂肪细胞会释放一种叫做activin A的蛋白质,损伤脂肪组织干细胞和脂肪组织的正常功能。正常衰老小鼠血液和脂肪组织中都存在activin A的增加。
 
随后,研究人员用JAK抑制剂药物治疗衰老小鼠(相当于80岁人类),结果发现该类药物能够下调activin A水平,并部分逆转脂肪组织的胰岛素抵抗情况,脂肪组织的胰岛素抵抗是导致老年人发生糖尿病的一个重要因素。研究人员还构建了一个在衰老细胞中表达药物激活基因的基因工程小鼠(INK-ATTAC小鼠),通过药物处理激活该基因能够去除衰老细胞,同时还发现activin A的水平出现下降,而促进胰岛素敏感性降低糖尿病风险的相关蛋白表达增加。这与JAK抑制剂对正常衰老小鼠的作用效果一致。
 
Dr. Kirkland最后指出:"这项工作表明靶向衰老细胞或它们产生的毒性物质可能是延缓,阻止,减轻或治疗衰老相关的干细胞和组织紊乱以及代谢疾病的一个非常具有前景的新方法。"

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2068450, encodeId=771a206845088, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Aug 12 09:21:00 CST 2016, time=2016-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972952, encodeId=8b9e19e295269, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 14 15:21:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57052, encodeId=70275e0527a, content=又出新招, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1f886e5d12c4637fe453ab919f018749/cb630129a57260ee2ad4a625e102da72.jpg, createdBy=c1d01679078, createdName=circlegirl, createdTime=Wed Jan 13 19:43:00 CST 2016, time=2016-01-13, status=1, ipAttribution=)]
    2016-08-12 clmlylxy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2068450, encodeId=771a206845088, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Aug 12 09:21:00 CST 2016, time=2016-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972952, encodeId=8b9e19e295269, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 14 15:21:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57052, encodeId=70275e0527a, content=又出新招, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1f886e5d12c4637fe453ab919f018749/cb630129a57260ee2ad4a625e102da72.jpg, createdBy=c1d01679078, createdName=circlegirl, createdTime=Wed Jan 13 19:43:00 CST 2016, time=2016-01-13, status=1, ipAttribution=)]
    2016-06-14 膀胱癌
  3. [GetPortalCommentsPageByObjectIdResponse(id=2068450, encodeId=771a206845088, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Fri Aug 12 09:21:00 CST 2016, time=2016-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972952, encodeId=8b9e19e295269, content=<a href='/topic/show?id=72d566e3a6' target=_blank style='color:#2F92EE;'>#eLife#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6673, encryptionId=72d566e3a6, topicName=eLife)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Tue Jun 14 15:21:00 CST 2016, time=2016-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57052, encodeId=70275e0527a, content=又出新招, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/1f886e5d12c4637fe453ab919f018749/cb630129a57260ee2ad4a625e102da72.jpg, createdBy=c1d01679078, createdName=circlegirl, createdTime=Wed Jan 13 19:43:00 CST 2016, time=2016-01-13, status=1, ipAttribution=)]
    2016-01-13 circlegirl

    又出新招

    0